Table 1. Antibody responses as measured with the hemagglutination-inhibition assay according to vaccine group.
| A/H1N1 | A/H3N2 | B | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PPV23 (n = 110) | PCV13 (n = 110) | p-value | PPV23 (n = 110) | PCV13 (n = 110) | p-value | PPV23 (n = 110) | PCV13 (n = 110) | p-value | |
| GMT (95% CI) | |||||||||
| At pre-vaccination | 22.3 (17.5–27.9) | 24.3 (19.4–30.3) | 0.603 | 54.1 (43.1–68.3) | 57.3 (45.1–72.8) | 0.737 | 26.6 (22.3–31.7) | 28.8 (23.4–35.0) | 0.555 |
| At post 1 moa) | 66.4 (55.1–80.1) | 89.9(74.5–108.4) | 0.026 | 149.5 (125.5–178.1) | 158.7 (133.2–189.1) | 0.634 | 48.7 (41.3–57.4) | 46.8 (39.7–55.1) | 0.735 |
| Seroprotection rate (95% CI, %) | |||||||||
| At pre-vaccination | 36.3 (27.4–45.1) | 38.9 (30.1–47.8) | 0.784 | 67.3 (58.4–76.1) | 69.9 (61.1–77.9) | 0.775 | 47.8 (38.1–56.6) | 47.8 (38.1–56.6) | > 0.990 |
| At post 1 mo | 76.4 (67.3–84.5) | 83.6 (77.3–90.0) | 0.238 | 93.6 (88.2–98.2) | 93.6 (88.2–98.2) | 1.000 | 70.0 (60.9–78.2) | 70.9 (62.7–79.1) | > 0.990 |
| Seroconversion rate (95% CI, %) | |||||||||
| At post 1 mo | 35.5 (26.4–44.5) | 48.2 (38.2–58.2) | 0.075 | 38.2 (29.1–48.2) | 41.8 (31.8–51.8) | 0.680 | 23.6 (16.4–32.7) | 20.9 (13.6–28.2) | 0.746 |
| GMT fold (95% CI) | |||||||||
| At post 1 mo | 2.9 (2.3–3.6) | 3.8 (3.0–4.7) | 0.104 | 2.7 (2.2–3.4) | 2.8 (2.3–3.5) | 0.835 | 1.8 (1.5–2.2) | 1.6 (1.4–2.0) | 0.588 |
PPV23, 23-valent polysaccharide pneumococcal vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; GMT, geometric mean titer; CI, confidence interval.
a)Post-vaccination GMT was adjusted according to pre-vaccination titer.